[
  {
    "info": {
      "NCT": "NCT05199584",
      "Protocol_No": "ENV-ONC-101",
      "jit": "Caris",
      "trial_name": "Endeavor Biomedicines ENV-ONC-101"
    },
    "disease": {
      "summary": "Solid Tumors ",
      "details": [
        {
          "code": "Solid Tumors",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT05199584",
      "title": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations",
      "current_status": "Recruiting",
      "status_verif_date": "August 2022",
      "last_update_date": "August 4, 2022",
      "trial_hold_status": "open",
      "sponsor": "Endeavor Biomedicines, Inc.",
      "brief_summary": "This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.",
      "conditions": "Solid Tumors With PTCH1 Loss-of-function Mutations",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "200 mg ENV-101",
          "drug": "ENV-101 (taladegib)",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "200 mg ENV-101",
              "Gene": "PTCH1",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Loss of Function",
              "summary": "PTCH1 Mutation Loss of Function  "
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "300 mg ENV-101",
          "drug": "ENV-101 (taladegib)",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "300 mg ENV-101",
              "Gene": "PTCH1",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Loss of Function",
              "summary": "PTCH1 Mutation Loss of Function  "
            }
          ]
        }
      ],
      "docs": "Q:\\MCK\\MOA\\Precision Oncology\\JIT Trials \\CarisPharmatechStudyList_2022-07-12.pdf",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT05199584\" target=\"_blank\">NCT05199584<\/a>"
    }
  }
]
